Merck Cash And Equivalents vs Treasury Stock Analysis
MRK Stock | USD 101.87 0.01 0.01% |
Merck financial indicator trend analysis is infinitely more than just investigating Merck Company recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Merck Company is a good investment. Please check the relationship between Merck Cash And Equivalents and its Treasury Stock accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Cash And Equivalents vs Treasury Stock
Cash And Equivalents vs Treasury Stock Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Merck Company Cash And Equivalents account and Treasury Stock. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Merck's Cash And Equivalents and Treasury Stock is -0.67. Overlapping area represents the amount of variation of Cash And Equivalents that can explain the historical movement of Treasury Stock in the same time period over historical financial statements of Merck Company, assuming nothing else is changed. The correlation between historical values of Merck's Cash And Equivalents and Treasury Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash And Equivalents of Merck Company are associated (or correlated) with its Treasury Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Treasury Stock has no effect on the direction of Cash And Equivalents i.e., Merck's Cash And Equivalents and Treasury Stock go up and down completely randomly.
Correlation Coefficient | -0.67 |
Relationship Direction | Negative |
Relationship Strength | Weak |
Cash And Equivalents
Treasury Stock
Most indicators from Merck's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Merck Company current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. At this time, Merck's Selling General Administrative is quite stable compared to the past year. Sales General And Administrative To Revenue is expected to rise to 0.18 this year, although the value of Tax Provision will most likely fall to about 2.2 B.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 35.1B | 41.9B | 44.0B | 46.2B | Total Revenue | 48.7B | 59.3B | 60.1B | 32.4B |
Merck fundamental ratios Correlations
Click cells to compare fundamentals
Merck Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Merck fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 84.4B | 91.6B | 105.7B | 109.2B | 106.7B | 60.3B | |
Short Long Term Debt Total | 26.3B | 31.8B | 33.1B | 30.7B | 36.3B | 38.1B | |
Other Current Liab | 14.9B | 16.3B | 16.9B | 18.0B | 15.5B | 16.3B | |
Total Current Liabilities | 22.2B | 27.3B | 23.9B | 24.2B | 25.7B | 13.3B | |
Total Stockholder Equity | 25.9B | 25.3B | 38.2B | 46.0B | 37.6B | 25.5B | |
Property Plant And Equipment Net | 15.1B | 18.0B | 19.3B | 21.4B | 24.5B | 25.7B | |
Net Debt | 16.7B | 23.7B | 25.0B | 18.0B | 29.4B | 30.8B | |
Retained Earnings | 46.6B | 47.4B | 53.7B | 61.1B | 53.9B | 32.6B | |
Cash | 9.7B | 8.1B | 8.1B | 12.7B | 6.9B | 5.6B | |
Non Current Assets Total | 56.9B | 63.8B | 75.4B | 73.4B | 74.5B | 41.1B | |
Non Currrent Assets Other | 5.3B | 9.2B | 8.1B | 7.7B | 9.2B | 6.1B | |
Cash And Short Term Investments | 10.5B | 8.1B | 8.1B | 13.2B | 7.2B | 7.3B | |
Net Receivables | 6.8B | 7.9B | 9.2B | 9.5B | 11.1B | 11.6B | |
Common Stock Shares Outstanding | 2.6B | 2.5B | 2.5B | 2.5B | 2.5B | 2.7B | |
Liabilities And Stockholders Equity | 84.4B | 91.6B | 105.7B | 109.2B | 106.7B | 60.3B | |
Non Current Liabilities Total | 36.2B | 38.9B | 43.6B | 38.9B | 43.3B | 45.5B | |
Inventory | 6.0B | 6.3B | 6.0B | 5.9B | 6.4B | 3.7B | |
Other Current Assets | 4.3B | 5.5B | 7.0B | 7.2B | 7.6B | 8.0B | |
Other Stockholder Equity | (16.3B) | (17.2B) | (12.9B) | (12.1B) | (12.9B) | (12.3B) | |
Total Liab | 58.4B | 66.2B | 67.4B | 63.1B | 69.0B | 72.5B | |
Total Current Assets | 27.5B | 27.8B | 30.3B | 35.7B | 32.2B | 19.2B | |
Short Term Debt | 3.6B | 6.4B | 2.4B | 1.9B | 1.7B | 2.3B | |
Intangible Assets | 14.2B | 14.6B | 22.9B | 20.3B | 18.0B | 14.3B | |
Accounts Payable | 3.7B | 4.6B | 4.6B | 4.3B | 3.9B | 2.8B | |
Property Plant And Equipment Gross | 15.1B | 18.0B | 37.5B | 39.4B | 41.3B | 43.4B | |
Accumulated Other Comprehensive Income | (6.2B) | (6.6B) | (4.4B) | (4.8B) | (5.2B) | (4.9B) | |
Short Term Investments | 774M | 1M | 0.0 | 498M | 252M | 239.4M | |
Other Liab | 12.7B | 12.1B | 11.7B | 9.1B | 10.5B | 10.2B | |
Other Assets | 5.3B | 7.8B | 9.4B | 7.4B | 8.5B | 5.5B | |
Long Term Debt | 22.7B | 25.4B | 30.7B | 28.7B | 33.7B | 17.2B | |
Good Will | 19.4B | 20.2B | 21.3B | 21.2B | 21.2B | 12.3B | |
Treasury Stock | (56.0B) | (56.8B) | (57.1B) | (56.5B) | (57.5B) | (54.6B) | |
Property Plant Equipment | 15.1B | 18.0B | 19.3B | 21.4B | 24.6B | 16.2B | |
Net Tangible Assets | (7.7B) | (9.5B) | 3.5B | 4.5B | 4.1B | 4.5B | |
Noncontrolling Interest In Consolidated Entity | 94M | 87M | 73M | 67M | 54M | 51.3M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.33) | Dividend Share 3.04 | Earnings Share 4.78 | Revenue Per Share 24.945 | Quarterly Revenue Growth 0.044 |
The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.